PALO ALTO, Calif. , Feb. 27, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today Read More

PALO ALTO, Calif. , Feb. 26, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today Read More

PALO ALTO, Calif. , Feb. 26, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today Read More

The lifetime prevalence of neck pain in the adult population is estimated to range from 14.2% to 71% with a mean of 48.5%. 2 There are currently no approved medical treatments for neck pain in the U.S. The study was a randomized, double-blind, placebo-controlled crossover trial performed at four Read More

PALO ALTO, Calif. , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today Read More

PALO ALTO, Calif. , Jan. 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today Read More

ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. 1 The U.S. oral migraine drug market size is estimated to be $2.3 billion in 2025. 2 According to market data from 2018, it was found that Read More

ZTlido ® is the most prescribed non-opioid, branded pain treatment prescribed by pain specialists. 1 Total ZTlido ® NRx (New Drug Prescription) market share for the non-opioid branded pain treatment market grew to 14.2% in October 2023 , compared to 11.8% in October 2022 according to prescription Read More

Gloperba ® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States 1 . Read More

National leading pharmacy chain to stock ELYXYB ® in most of their stores throughout the U.S. Previously, Scilex Holding Company announced pharmacy initiative to stock ELYXYB® for the other leading pharmacy chain in the U.S.   Scilex is also in the process of negotiating similar potential stocking Read More